Q-omics provides the consensus-scored TMEM50B profile across patient tissues and cancer cell-line models. TMEM50B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TMEM50B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TMEM50B RNA expression shows 20,159 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KIRC, and ACC as cancer lineages where TMEM50B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM50B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM50B survival associations across molecular data types. TMEM50B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM50B RNA expression–survival associations across cancer types. High TMEM50B expression shows unfavorable associations in STAD, LGG, UVM and ACC, but favorable associations in LUAD and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TMEM50B RNA expression.
This table summarizes TMEM50B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM50B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM50B shows lower tumor expression in KIRC, KICH, THCA, LUSC and KIRP and higher tumor expression in LIHC. The KIRC box plot shows higher TMEM50B RNA expression in normal versus tumor tissue (log2 FC = −1.067, t-test p < 0.001).
This table shows molecular features associated with TMEM50B in patient tissues and cancer cell lines. In patient samples, TMEM50B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM50B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
